The Interplay between Chagas Disease and Cardiovascular Disorders: A Comprehensive Review
Main Article Content
Abstract
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, is a neglected tropical disease prevalent in Latin America. While traditionally known for its acute and chronic manifestations, recent research has shed light on its association with cardiovascular disorders. This review aims to explore the intricate relationship between Chagas disease and cardiovascular diseases, including cardiomyopathy, arrhythmias, and thromboembolic events. We delve into the epidemiology, pathophysiology, clinical manifestations, diagnostic challenges, and management strategies of these coexisting conditions. Additionally, we discuss the impact of Chagas disease on the cardiovascular system in the context of global health and highlight the importance of integrated care approaches for affected individuals.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Mendez GF, Cowie MR. The epidemiological features of heart failure in developing countries: a review of the literature. Int J Cardiol. 2001;80:213–9. doi: 10.1016/S0167-5273(01)00497-1.
II. Ribeiro AL, Nunes MP, Teixeira MM, Rocha MO. Diagnosis and management of Chagas disease and cardiomyopathy. Nat Rev Cardiol. 2012;9:576–89. doi: 10.1038/nrcardio.2012.109.
III. Bocchi EA, Arias A, Verdejo H et al. The reality of heart failure in Latin America. J Am Coll Cardiol. 2013;62:949–58. doi: 10.1016/j.jacc.2013.06.013.
IV. Traina MI, Sanchez DR, Hernandez S et al. Prevalence and impact of Chagas disease among Latin American immigrants with nonischemic cardiomyopathy in Los Angeles, California. Circ Heart Fail. 2015;8:938–43.
doi: 10.1161/CIRCHEARTFAILURE.115.002229.
V. Bocchi EA. Heart failure in South America. Curr Cardiol Rev. 2013;9:147–56.
doi: 10.2174/1573403X11309020007.
VI. Stanaway JD, Roth G. The burden of Chagas disease: estimates and challenges. Glob Heart. 2015;10:139–44.
doi: 10.1016/j.gheart.2015.06.001.
VII. Tanowitz HB, Machado FS, Spray DC et al. Developments in the management of Chagas cardiomyopathy. Expert Rev Cardiovasc Ther. 2015;13:1393–409.
doi: 10.1586/14779072.2015.1103648.
VIII. Bern C. Chagas’ disease. N Engl J Med. 2015;373:456–66. doi: 10.1056/NEJMra1410150.
IX. Shen L, Ramires F, Martinez F et al. contemporary characteristics and outcomes in chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy. Circ Heart Fail. 2017;10:e004361. doi: 10.1056/NEJMra1410150.
X. Ramires FJA, Martinez F, Gomez EA et al. Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Fail. 2018;5: 1069–71.
doi: 10.1002/ehf2.12355.
XI. Pan American Health Organization. General Information – Chagas Disease. 2011. https://www.paho.org/hq/index.php?option=com_content&view=article&id=5856:2011-informacion-general-enfermedad-chagas&Itemid=0&lang=enalable Available at. 12. WHO, Geneva: 2002.. WHO. TDR Strategic Directions: Chagas Disease
XII. WHO. Control of Chagas disease : report of a WHO expert committee [meeting held in Buenos Aires from 16 to 20 October 1989] https://apps.who.int/iris/handle/10665/37686
XIII. Jörg M, Storino R. Consensus on Chagas disease: Chagas disease in the 21st century. Consensus on an unfinished subject. Revista Argentina de Cardiologia. 2002;70(Suppl 1):9–10.
XIV. Barbosa MP, Carmo AA, Rocha MO, Ribeiro AL. Ventricular arrhythmias in Chagas disease. Rev Soc Bras Med Trop. 2015;48:4–10. doi: 10.1590/0037-8682-0003-2014.
XV. Anselmi A, Moleiro F, Mendoza I. Clinical picture of Chagas disease. Differential diagnosis with dilated or congestive cardiomyopathy. Revista Latina Cardiología. 1982;3:97–104.